Tomedes Ensures Regulatory Compliance in Medical Device IFU Translation from English to Brazilian Portuguese

The Client

• Company name: Vantara Medical Devices (pseudonym)

• What does the company do? A U.S.-based medical device manufacturer specializing in minimally invasive diagnostic equipment for use in hospital and outpatient clinical settings.

• Deadline: 10 business days

• What do they need? Vantara required a certified Brazilian Portuguese translation of a 47-page Instructions for Use document for a diagnostic device pending market authorization from ANVISA, Brazil's National Health Surveillance Agency. The IFU covered device description and intended use, contraindications and safety warnings, step-by-step operating procedures, cleaning and sterilization protocols, troubleshooting guidance, and technical specifications. The translated document would be submitted directly as part of Vantara's ANVISA registration dossier, meaning it had to meet both the linguistic standards of Brazilian Portuguese and the specific formatting and terminology requirements of Brazilian medical device regulation.

The Challenges

Translating a medical device IFU for regulatory submission in Brazil is not the same as translating a product manual for general use. The document is a regulatory artifact – reviewed by ANVISA evaluators who will assess not just whether the content is accurate, but whether the terminology, structure, and language conform to Brazilian regulatory conventions. Vantara faced three challenges that required more than a standard medical translation workflow.

1. First, ANVISA-specific terminology and regulatory language conventions

Brazil's medical device regulatory framework (governed by RDC 751/2022 and its associated normative instructions) uses a defined set of Portuguese-language terms for device classifications, risk categories, intended use descriptions, and safety warning language. These terms are not simply translations of their English-language FDA equivalents. ANVISA evaluators expect to see the established Brazilian regulatory vocabulary in registration dossiers, and documents that use calque translations of U.S. regulatory language (even when linguistically accurate) can trigger clarification requests or delays in the evaluation process. The translation team needed linguists who understood ANVISA's regulatory language conventions, not translators working from general medical dictionaries.

2. Second, safety-critical warning and contraindication content requiring zero tolerance for ambiguity

The IFU included 23 distinct safety warnings, contraindication statements, and precautionary notices – covering electrical safety, sterility requirements, single-use restrictions, and patient population exclusions. In medical device documentation, warning language is not interchangeable. The distinction between "warning," "caution," and "note" carries defined meaning under IEC 82079-1, the international standard for instructions for use, and the Brazilian Portuguese equivalents of these signal words must map precisely to the same hierarchy. A warning rendered as a caution, or a contraindication softened through imprecise word choice, could misrepresent the device's risk profile to clinical users and create both patient safety and regulatory liability issues for Vantara.

3. Lastly, sterilization and cleaning protocol language requiring technical precision across multiple methods

The IFU included detailed cleaning, disinfection, and sterilization protocols covering three separate methods (manual cleaning, automated washer-disinfection, and steam sterilization) each with specific concentration ranges, exposure times, temperature parameters, and cycle validation requirements. This content sits at the intersection of medical device science, infection control practice, and regulatory compliance. Imprecise rendering of a concentration value, a cycle parameter, or a sterilization method designation could compromise device reprocessing in the field. The translation required a linguist with direct familiarity with medical device reprocessing terminology in Brazilian Portuguese, not general clinical translation experience.

Why Tomedes?

Vantara selected Tomedes based on its ISO 17100:2015 certification and its documented experience with medical device regulatory translation for LATAM markets. The ANVISA submission context in particular required a translator with direct familiarity with Brazilian medical device regulatory language, a specialization that Tomedes was able to source from its network of subject-matter expert linguists with life sciences backgrounds.

The project was assigned a dedicated project manager with experience coordinating medical device translation projects for regulatory submissions, who structured the workflow to include a terminology alignment stage before translation began and a regulatory language review stage after the main translation pass.

The Solution

1. First, a pre-translation regulatory terminology alignment

Before translation began, Tomedes conducted a terminology alignment session with Vantara's regulatory affairs team to establish the approved Brazilian Portuguese equivalents for the device's core technical vocabulary – device classification terms, intended use language, and the specific designations for device components referenced throughout the IFU. Tomedes cross-referenced these terms against ANVISA's published guidance documents and the established Brazilian Portuguese terminology used in analogous registered device dossiers. The resulting 54-term glossary was approved by Vantara's regulatory affairs lead before translation started, ensuring that the linguist team was not making independent judgment calls on terms that carried regulatory weight. The glossary was applied consistently across the full IFU using the Key Terms Glossary tool.

2. Second, a lead translator with medical device regulatory specialization

The main translation pass was handled by a linguist with a background in Brazilian medical device regulatory documentation and direct familiarity with ANVISA submission requirements and IEC 82079-1 signal word conventions. The safety warnings, contraindication statements, and precautionary notices were treated as a discrete workstream within the project – translated against the signal word hierarchy, reviewed for alignment with ANVISA's established warning language conventions, and signed off by the lead translator before being integrated with the rest of the IFU. The sterilization and cleaning protocol sections received dedicated review against Brazilian infection control terminology standards. This separation ensured that the highest-stakes content in the document received focused attention rather than being processed as part of a continuous document flow.

3. Lastly, a regulatory language review by a second medical device specialist

Following the main translation pass, a second linguist with regulatory review experience conducted a full document review focused specifically on ANVISA terminology alignment – checking that all device classification language, intended use descriptions, and safety warning signal words conformed to Brazilian regulatory conventions rather than direct translations of FDA-equivalent language. The reviewer produced 18 targeted adjustments, primarily terminology substitutions where the lead translator's technically accurate rendering differed from the established ANVISA regulatory vocabulary. The final document was delivered as a formatted PDF and editable DOCX, ready for direct inclusion in Vantara's ANVISA registration dossier.

Conclusion

Regulatory submissions do not get second chances on terminology. When Vantara's ANVISA dossier was assembled, the IFU read in Brazilian Portuguese that it was written for Brazilian regulatory evaluators – using the vocabulary, signal word conventions, and technical language that ANVISA evaluators expect to see in a compliant registration package. The document was submitted as part of Vantara's market authorization application on schedule, with no terminology clarification requests issued by ANVISA during the initial dossier review.

Are you preparing a medical device IFU, labeling package, or regulatory dossier for the Brazilian market or other LATAM jurisdictions? Contact Tomedes today for a free consultation.

Key Details